Medicare dropped a confidentiality requirement that banned pharmaceutical companies from publicly discussing drug price negotiations set to begin this fall.
Drugmakers had sued the federal government, arguing that the requirement violated the First Amendment. In initial guidance released in March, Medicare had forbidden the industry from publicly disclosing information on the lower price initially offered by the federal government for drugs targeted under the program, as well as the government's reasons for selecting that price point.
Wij hebben dit nieuws samengevat zodat u het snel kunt lezen. Bent u geïnteresseerd in het nieuws, dan kunt u hier de volledige tekst lezen. Lees verder: